The optimal treatment strategy in early psoriatic arthritis remains unknown. We aimed to assess whether the combination of methotrexate and golimumab plus corticosteroids is superior to methotrexate plus corticosteroids in reducing disease activity in early, untreated psoriatic arthritis.

To describe the prevalence of gastrointestinal (GI) symptoms in SSc and Very Early Diagnosis of SSc (VEDOSS), identify clinical and serological features associated with GI involvement and explore a cranio-caudal pattern of symptom distribution, using data from the Italian SPRING-SIR registry.

SLE is a heterogeneous autoimmune disorder often complicated by vascular events, with or without antiphospholipid antibody syndrome (APS). This study aimed to explore subclinical venous involvement in SLE using biochemical and imaging modalities, focusing on vein wall thickness (VWT) and inflammation-related biomarkers.

This study aimed to establish a risk prediction model for the relapse of anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD).

Venous thromboembolism (VTE) is a known complication of SLE, yet there is a lack of high-quality studies specifically focused on LN. This study aimed to assess the frequency of VTE in patients with LN and identify risk factors for its development.

To assess the relation between the proportion of myeloid-derived suppressor cells (MDSCs), monocyte subsets, and the clinical phenotypes and disease activity of psoriatic disease (PsD), including psoriasis (PsO) and PsA.

Methods for high-dimensional immune-cell profiling have advanced dramatically in the past decade. Studies of tissue and blood samples from patients with rheumatic diseases have revealed stereotyped features of immune dysregulation in individual diseases and in subsets of patients who share diagnosis of a heterogeneous disease. Translating immunological patterns into clinically implementable, actionable biomarkers has the potential to improve detection and quantification of pathological immune activity and selection of appropriate treatments for autoimmune rheumatic diseases. For example, cytometric features can be used to distinguish the various forms of inflammatory arthritis, stratify subsets of patients with rheumatoid arthritis or subsets of patients with systemic lupus erythematosus and predict treatment responses. Cellular immune profiling also enables the identification of specific features of immune dysregulation in individuals with rare, undiagnosed, inflammatory diseases. Several paths might lead to translation of discoveries from broad immune profiling into clinical tests to interrogate immune activation in people with rheumatic diseases.

Severe forms of systemic JIA (sJIA), also called paediatric-onset Still's disease are associated with two major life-threatening complications: macrophage activation syndrome (MAS) and severe lung disease. Patients are usually resistant to conventional synthetic (cs) DMARDs, biologic (b) DMARDs, and targeted synthetic (ts) DMARDs. Recently, allogeneic haematopoietic stem cell transplantation (HSCT) has been performed in a small number of patients with refractory and life-threatening disease. We aimed to report outcomes and complications of allogeneic HSCT in patients with severe, refractory sJIA treated at our centre.